PROCEED-UC v2.0

  • Research type

    Research Study

  • Full title

    Prognostic value of Red Density in Ulcerative Colitis

  • IRAS ID

    276046

  • Contact name

    Uday Shivaji

  • Contact email

    uday.shivaji@uhb.nhs.uk

  • Sponsor organisation

    UZ Leuven

  • Duration of Study in the UK

    3 years, 6 months, 1 days

  • Research summary

    Ulcerative Colitis (UC) is a chronic, relapsing disease. Patients are monitored but the assessment of disease activity is challenging. Current endoscopic tools are all based on the subjective assessment of the observer. There is some indication that better outcomes can be achieved where complete endoscopic remission is observed compared to endoscopic improvement alone. Therefore, a more objective assessment of disease activity is required.
    Red Density (RD) is an objective real time digital endoscopic tool. It is integrated in a prototype endoscope which includes a processor, and extracts pixel data from high definition white light endoscopic images to provide an endoscopic score displayed as a colour map.
    RD has been shown to correlate with UCEIS and MES scores and to detect changes in disease activity following initiation of therapy.
    Therefore, the PROCEED-UC study aims to further validate the clinical predictive value of the RD score for sustained clinical and endoscopic remission.
    In the UK, patients with UC which is currently in remission, will be recruited from two centres. Study procedures will be carried out as part of standard care for patients with UC, and it is not anticipated that further hospital visits will be required.
    Patients will undergo endoscopy at baseline using the RD scope. Patients will then be followed up for 52 weeks or until clinical relapse occurs. A routine clinic visit, will occur at week 26 and a further endoscopy will be done at week 52. Interim follow ups at week 13 and 39 will be done by review of notes and telephone contact with patient. Standard care samples will be taken: biopsies at endoscopy visits, and blood and stool samples at all timepoints.
    The primary endpoint is the number of patients with sustained clinical remission.

  • REC name

    East of England - Cambridgeshire and Hertfordshire Research Ethics Committee

  • REC reference

    20/EE/0111

  • Date of REC Opinion

    19 May 2020

  • REC opinion

    Further Information Favourable Opinion